<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872624</url>
  </required_header>
  <id_info>
    <org_study_id>13-0150</org_study_id>
    <nct_id>NCT01872624</nct_id>
  </id_info>
  <brief_title>Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema</brief_title>
  <official_title>Bone-marrow Derived Mesenchymal Stromal Cells Associated With One-way Endobronchial Valves in Patients With Pulmonary Emphysema: Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Council, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pontifícia Universidade Católica do Paraná</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combined use of one-way endobronchial valves and bone-marrow derived mesenchymal stromal
      cells in patients with severe pulmonary emphysema is safe and will contribute to increase
      quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to testing the safety of one-way endobronchial valves combined with bone-marrow
      derived mesenchymal stromal cells, the study will determine the systemic inflammatory
      potential of cell therapy measured by C-reactive protein levels (CRP), erythrocyte
      sedimentation rate (ESR) and complete blood count in peripheral blood. Finally, the study
      will aim at determining if other markers of inflammatory response and remodeling are
      modulated by this therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of lung deficits during the procedure and/or in the 4 months follow-up</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>120 days</time_frame>
    <description>St. George Respiratory Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>120 days</time_frame>
    <description>Spirometry, flow-volume curve, post-bronchodilator test, determination of residual volume, airway resistance by plethysmography, diffusing capacity of the lung for carbon monoxide, and six-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>120 days</time_frame>
    <description>Collection of blood samples for determination of C-reactive protein (CRP), erythrocyte</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pulmonary Emphysema</condition>
  <arm_group>
    <arm_group_label>Valves plus cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bronchoscopy Five patients will be selected to receive bone-marrow derived mesenchymal stromal cells delivered bronchoscopically right before insertion of one-way endobronchial valves.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valves plus saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bronchoscopy Five patients will be selected for treatment with one-way endobronchial valves only, with saline injected prior to valve insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopy</intervention_name>
    <description>Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.</description>
    <arm_group_label>Valves plus cells</arm_group_label>
    <arm_group_label>Valves plus saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of severe heterogeneous emphysema (heterogeneity &gt; 15%), with heterogeneity
             defined as the difference between lobes in the percent area covered by parenchymal
             density greater than -950 Hounsfield Units.

          -  Estimation of collateral ventilation based on fissure with integrity ≥ 75%.

          -  Total lung capacity&gt; 100% predicted.

          -  Residual volume&gt; 150% predicted.

          -  Forced expiratory volume at the first minute &lt;45% predicted.

          -  Diffusing capacity of the lungs for carbon monoxide &lt;45% predicted.

          -  Optimal medical treatment.

          -  Limitations in daily physical activities.

          -  Minimum of 4 months without smoking

          -  Having family support.

          -  Stage ≥ 2 in modified Medical Research Council Dyspnea Scale (MMRC).

        Exclusion Criteria:

          -  Homogenous emphysema.

          -  Presence of collateral ventilation.

          -  Use of systemic corticosteroids (prednisone&gt; 20mg/day or equivalent).

          -  Pulmonary or extrapulmonary infection.

          -  Coronary heart disease and/or severe ventricular dysfunction.

          -  Significant renal or liver disease.

          -  Immunosuppressive disease.

          -  Active smoking.

          -  Cancer prognosis with survival &lt;2 years.

          -  Psychosocial problems.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo G Oliveira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia RM Rocco, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pontificia Universidade Catolica do Parana</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80215-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-902</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Abreu SC, Antunes MA, Pelosi P, Morales MM, Rocco PR. Mechanisms of cellular therapy in respiratory diseases. Intensive Care Med. 2011 Sep;37(9):1421-31. doi: 10.1007/s00134-011-2268-3. Epub 2011 Jun 9. Review.</citation>
    <PMID>21656291</PMID>
  </reference>
  <reference>
    <citation>de Oliveira HG, Macedo-Neto AV, John AB, Jungblut S, Prolla JC, Menna-Barreto SS, Fortis EA. Transbronchoscopic pulmonary emphysema treatment: 1-month to 24-month endoscopic follow-up. Chest. 2006 Jul;130(1):190-9.</citation>
    <PMID>16840401</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas de Porto Alegre</investigator_affiliation>
    <investigator_full_name>Hugo Goulart de Oliveira</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

